A Commercial Perspective on Resetting Stem Cell Clocks
Andrew Pollack of the New York Times wrote a piece Thursday that contained some interesting comments from California folks on mice and resetting their stem cell clocks.
Some excerpts:
"'Once you muck around with the genome, all bets are off,' said Dr. Thomas B. Okarma, chief executive of Geron, a company trying to develop medical treatments from human emb…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.